Pharmexcil’s Chintan Shivir Outlines India’s Vision to Be the Global Benchmark for Pharmaceutical Quality and Reliability

Hyderabad, April 4, 2026: The Chintan Shivir on the Pharmaceutical Sector, organized by the Pharmaceutical Export Promotion Council of India (PHARMEXCIL), with the support of the Ministry of Commerce & Industry, Government of India, concluded successfully today in Hyderabad. This event marked the continuation of the series of discussions, following successful editions in Chandigarh and Ahmedabad, and served as a platform for strengthening India’s pharmaceutical export agenda.
The inaugural session, chaired by Rajesh Agrawal, Commerce Secretary, Department of Commerce and Industry, Ministry of Commerce & Industry, set the tone for the day’s deliberations. During his address, Shri Agrawal underscored the government's commitment to reinforcing India’s position in global pharmaceutical exports through continuous policy support, regulatory alignment, and digital transformation.
“In a rapidly evolving and geopolitically dynamic global environment, India’s pharmaceutical industry is uniquely positioned to strengthen its global leadership by deepening collaboration with the government and progressively reducing supply chain dependencies. Building on its strong foundation of cost competitiveness, the next phase of growth lies in elevating India’s position as a trusted global benchmark for quality and reliability. By continuously strengthening the ecosystem and staying aligned with global advancements, the industry is well on track to transition towards high-value segments such as biologics and biosimilars. As India moves beyond its generic’s legacy, it has a significant opportunity to lead the next wave of pharmaceutical innovation, reinforcing its role as a resilient, future-ready, and globally influential healthcare powerhouse. Chintan Shivirs have traditionally been convened by our Honourable Prime Minister to deliberate on India’s pathway to progress and long-term national priorities. Inspired by this vision, we have adopted the same concept within the pharmaceutical industry, recognising the pivotal role the sector plays in advancing India’s growth story.” said Rajesh Agrawal, Commerce Secretary, Department of Commerce and Industry, Ministry of Commerce & Industry.
“Despite current challenges such as supply chain stress and the geopolitical disruptions, India's export sector remains resilient, with positive growth trends. The Pharmexcil Chintan Shivir provided a platform for focused, forward-looking dialogues, where we deliberated on the roadmap for the coming years. The event outlined a strategic vision for the pharmaceutical sector, emphasizing value creation through innovation and enhanced market access via Free Trade Agreements (FTAs). With ongoing policy support and a forward-looking approach, we are confident in achieving a successful conclusion to the financial year,” said Namit Joshi, Chairman, Pharmexcil.
“Indian pharmaceutical exports reached nearly USD 28.29 billion by February this financial year, growing 5.6% compared to last year. The sector, valued at approximately USD 60 billion, is projected to reach USD 130 billion by 2030. Despite global challenges, pharmaceutical exports have maintained strong momentum, with a 5.6% growth during April–February FY26,” said Raja Bhanu, Director General, Pharmexcil.
The event featured focused sessions on key areas of strategic importance, including the Impact of Artificial Intelligence and Digital Transformation on Global Harmonisation in Pharmaceutical Regulatory Affairs, where industry experts explored how AI and digital tools can streamline regulatory processes, enhance compliance, and support India’s push for greater market access. Discussions also centered on the role of the Export Promotion Mission in empowering MSMEs for global markets, the effective utilisation of Free Trade Agreements (FTAs) signed by India to boost pharma exports, and the importance of the Trade Connect e-platform to explore the markets abroad. This highlighted the evolving role of the Directorate General of Foreign Trade (DGFT) in promoting exports and ensuring alignment with global standards. Furthermore, stakeholders deliberated on Strategies for Enhancing Pharmaceutical Exports, with an emphasis on improving regulatory compliance, expanding market access, and strengthening government support to elevate India’s pharmaceutical export footprint.
Hyderabad, a city that has established itself as a leading pharmaceutical hub, continues to play a pivotal role in India’s pharma sector. The city is home to a thriving ecosystem of pharmaceutical manufacturing, research, and development, hosting several of the world’s largest pharmaceutical companies. With a rich legacy of pharmaceutical innovation and infrastructure, Hyderabad accounts for a significant share of India’s total pharmaceutical production and exports. The city’s robust regulatory frameworks, skilled workforce, and strategic location have contributed to its growing stature as a global leader in drug manufacturing, particularly in the fields of bulk drugs, biosimilars, and generics.
The Hyderabad Chintan Shivir also featured engaging discussions with senior representatives from regulatory bodies, industry leaders, and market experts, aimed at refining India’s pharmaceutical export strategy. These sessions highlighted the need for continued modernization of India’s regulatory frameworks, reduction of procedural bottlenecks, and bolstering innovation to tap into emerging global market opportunities.
Pharmexcil also provided an update on its flagship event, IPHEX 2026, which will showcase India’s pharmaceutical manufacturing strengths, emphasizing innovation, higher-value offerings, and enhanced compliance standards. As global markets continue to shift towards complex generics and biosimilars, IPHEX 2026 will serve as a platform for exploring new business opportunities and reinforcing India’s role as a reliable global pharmaceutical partner.
The Chintan Shivir in Hyderabad concluded on a high note, with stakeholders across the pharmaceutical sector agreeing that continued collaboration between the government and industry is key to achieving India’s ambitious export growth goals. The event has paved the way for actionable insights and strategic roadmaps that will drive India’s pharmaceutical sector towards greater global prominence in the years ahead.